Novel cyclodextrin-based excipients for drug formulations
Tech ID #: 1094.2 CONNECT WITH A MANAGER FOR LICENSING
Cyclodextrins (CDs) are cyclic oligosaccharides used for the improvement of water-solubility and bioavailability of medicinal products. At least six types are available on the market. This class of excipients can be readily tailored for use in drug formulations.
Description of Technology
The CC Ling group in the Department of Chemistry at the University of Calgary develops novel delivery technologies of modern medicines to improve their bioavailability and therapeutic efficacy while minimizing their side effects. They have designed several families of patent protected, uniquely modified cyclodextrins, with rationally designed structures and demonstrated properties that are suitable for applications as excipients. Our materials readily form inclusion complexes with a wide variety of active pharmaceutical ingredients and improve their water solubility, stability and bioavailability. They can be further developed as scavenger medicine to remove undesired metabolites or drugs from the body.
This technology is currently available for exclusive world-wide licensing and co-development. We are seeking a commercial partner interested in commercializing our cyclodextrin-based technologies.
Areas of Application
- Drug delivery
- Rescue medicines
- US 9,950,080B2
- Three patent families with broad IP protection in Canada, United States, Australia, Europe and Japan
- Monodisperse, single molecule excipients with variable cavity sizes and linker lengths
- Polyanionic, highly water soluble and do not form self-inclusion complexes
- Very strong binding affinities for some groups of medicines
- Modular, scalable synthesis demonstrated at the KG scale
- Proprietary “catch and release” technologies for fast binding affinity determination and screening of drug candidates for inclusion by mass spectrometry
- Lower viscosity, higher solubility than commercial excipients
- Low toxicity
Stage Of Development
- KG scale synthesis demonstrated and validated with an external partner
- No toxicity in animal models based on one time maximum injection and hemolysis experiments
- Lead compound is currently being characterized as an excipient with a CRO,